Developmental Therapeutics Program at the NCI: molecular target and drug discovery process
- 1 April 2002
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 16 (4), 520-526
- https://doi.org/10.1038/sj.leu.2402464
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 18 references indexed in Scilit:
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsBritish Journal of Cancer, 2001
- Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory NeoplasmsJournal of Clinical Oncology, 2001
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000
- Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USAAnnals of Oncology, 1999
- Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.Journal of Clinical Investigation, 1998
- An Information-Intensive Approach to the Molecular Pharmacology of CancerScience, 1997
- In vivo cultivation of tumor cells in hollow fibersLife Sciences, 1995
- Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.Journal of Clinical Investigation, 1995
- Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE AlgorithmJNCI Journal of the National Cancer Institute, 1989
- Selection of molecular fragment features for structure-activity studies in antitumor screeningJournal of Chemical Information and Computer Sciences, 1981